KALA BIO, Inc. Common Stock (KALA)
Kala Bio, Inc. (KALA) is a biotechnology company focused on developing innovative gene therapies and biologic treatments. The company aims to address unmet medical needs by leveraging cutting-edge genetic engineering technologies to create therapies for rare and serious diseases.
Company News
Clinical-stage biotech Kala Bio reported a Q2 2025 net loss of $1.71 per share, with continued focus on developing KPI-012 for persistent corneal epithelial defects. The company completed patient enrollment in its Phase 2b CHASE trial and expects topline results by September 2025.
KALA BIO, Inc. announced the resignation of its CEO Mark Iwicki and the appointment of Todd Bazemore as interim CEO. Iwicki will continue to serve as Chair of the Board. Bazemore has over 30 years of experience in the pharmaceutical industry and will lead the company as it approaches topline data from the ongoing Phase 2b clinical trial of its lead product candidate KPI-012 for the treatment of persistent corneal epithelial defect (PCED).
The mean of analysts' price targets for KALA BIO (KALA) points to a 152.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Within the last quarter, Kala Pharmaceuticals (NASDAQ:KALA) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 2 0 0 0 0 3M Ago 0 0 0 0 0 In the last 3 months, 4 analysts have offered 12-month price targets for Kala Pharmaceuticals. The company has an average price target of $21.0 with a high of $22.00 and a low of $20.00. Below is a summary of how these 4 analysts rated Kala Pharmaceuticals over the past 3 months. The greater the number of bullish ratings, the ...Full story available on Benzinga.com